Consistent with other studies, mutated TP53 was enriched in EGFR-mutated NSCLC, occurring in 57.8% of the patients at baseline, which falls within the reported range of 54.6%%-64.6% for mutated TP53. 41–43 The presence of mutated TP53 is reported to be an adverse predictor of TKI therapeutic outcome in NSCLC.26 In this study, dual inhibition likely contributed to the reduction in the occurrence of TP53 mutations, resulting in a lower rate of mutated TP53 at the first posttreatment efficacy evaluation and at the time of disease progression. This evidence concerns the gene EGFR and non-small cell lung carcinoma.